Miao Gao

Miao Gao

Auto-generated profile, based on publicly available information

Miao Gao

University of Leeds

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in Diabetes Care
Verified
Journal Article
Closed access
MGMiao Gao
Miao Gao
SSSwathi Saravanan
Swathi Saravanan
TMTheresa Munyombwe
Theresa Munyombwe
JSJane Speight
Jane Speight
AHAndrew J. Hill
Andrew J. Hill
RARamzi Ajjan
Ramzi Ajjan
BACKGROUND: Use of technology is central to the management of type 1 diabetes (T1D), while patient reported outcomes measures (PROMs) can support in the management of these individuals. PURPOSE: To assess the effect of diabetes technologies on patient-reported outcome measures (PROMs) in type 1 diabetes (T1D). DATA SOURCES: Cochrane Library CENTRAL, Embase, MEDLINE, Scopus, and Web of Science were searched for relevant articles from 2013 to August 2025. STUDY SELECTION: We included longitudinal diabetes technology studies assessing validated PROMs in nonpregnant adults with T1D. DATA EXTRACTION: Study characteristics and PROM data were extracted, and standardized mean differences (SMDs) for PROs were pooled using a random-effects meta-analysis. DATA SYNTHESIS: We identified 4,885 articles, comprising 81 independent studies (n = 19,148 participants) and 70 different PROMs. The Hypoglycemia Fear Survey (HFS) was most commonly used (k = 39 studies), followed by the Diabetes Treatment Satisfaction Questionnaire (status [DTSQs] or change version [DTSQc]; k = 38), Diabetes Distress Scale (DDS; k = 25), and Problem Areas in Diabetes (PAID) scale (k = 24). Technology use was associated with lower HFS total score compared with control (SMD −0.177; 95% CI −0.319, −0.036; P = 0.014; I2 = 0.0%), with the largest effect observed in automated insulin device users. A moderate positive effect of diabetes technologies was observed on DTSQs and DTSQc scores (SMD 0.429; 95% CI 0.206, 0.653; P < 0.001; I2 = 72.3%), with a small to moderate reduction in DDS and PAID scores (SMD −0.265; 95% CI −0.363, −0.166; P < 0.001; I2 = 0.0%). LIMITATIONS: Differences in type of technology, varied use and incomplete reporting of PROMs, and different duration of studies. CONCLUSIONS: Diabetes technologies offer psychological benefits in adults with T1D. The large number of reported PROMs suggests a need to standardize their use.

9 April 2026 in European Cardiology Review
Verified
Journal Article
Open access
PDF file
MGMiao Gao
Miao Gao
TSTanjot Singh
Tanjot Singh
RARamzi Ajjan
Ramzi Ajjan
Obesity is a modifiable driver of cardiovascular disease and coexistent diabetes adds to adverse vascular outcomes. Guidelines uniformly highlight weight management as a cornerstone of cardiovascular prevention and recommend stepwise strategies starting with lifestyle modifications, then pharmacotherapies, followed by bariatric surgery in non‑responders. Despite a large body of evidence, use of weight loss cardiovascular protective agents remains low in clinical practice due to high costs and limited familiarity. Additional barriers include inadequate prioritisation of weight management in cardiac care, fragmented cross-specialties coordination, and lack of specific guidance in some high‑risk groups (e.g. those with type 1 diabetes). Given various difficulties, implementation of effective anti-obesity strategies remains suboptimal and requires more support of non-specialists together with greater efforts to align healthcare provider practices and system-level policies to ensure the delivery of equitable and sustainable weight loss interventions at scale.